# **Special Issue**

# Vaccines for the Vulnerable Population

# Message from the Guest Editor

This Special Issue seeks to collect contemporary information on vaccination for vulnerable populations. We invite contributions from immunology and vaccinology experts to submit their original research, reviews, perspectives, and clinical trial reports. We are particularly interested in knowledge on the following themes: 1. The pathogen- or drug-induced mechanisms that may impact vaccine responsiveness; 2. Data on the immunogenicity and safety of standard and new vaccines; 3. Identifying biomarkers that could lead to more effective vaccination strategies.

#### **Guest Editor**

Dr. My Kieu Ha

Vaccine and Infectious Disease Institute, University of Antwerp, 2000 Antwerpen, Belgium

## Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/226264

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

#### **Author Benefits**

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

